Search - tctmd.com

Displaying 21 - 40 of 444

Sort: Relevancy | Date

Presentation TCT 2016

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Presenter: John A. Bittl, Daniel I. Simon, Robert W. Yeh

October 30, 2016

Presentation TCT 2016

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Presenter: John A. Bittl, Daniel I. Simon, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Salvatore Cassese

October 30, 2016

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Laura Mauri

October 30, 2016

Presentation TCT 2016

Debate: Making the Case for Very Limited Use of Cangrelor!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Sorin J. Brener

October 30, 2016

Presentation TCT 2016

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2016

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Presenter: Deepak L. Bhatt, Christian W. Hamm

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Industry News

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

October 30, 2016

News Industry News

Academic Research Organization HCRI Changes Name to The Baim Institute for Clinical Research

October 27, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Daily News

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Shelley Wood

October 07, 2016

Advertisement

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Debate: Making the Case for Very Limited Use of Cangrelor!

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

Academic Research Organization HCRI Changes Name to The Baim Institute for Clinical Research

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content